0R0H.LSE Thermo Fisher Scientific Inc.
- Market cap
- -
- P/E
- 35.2x
- P/B
- -
- ROE
- 12.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.
Is 0R0H.LSE undervalued?
Graham numberThe Graham number of Thermo Fisher Scientific Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Thermo Fisher Scientific Inc. fundamental analysis
No fundamental analysis for Thermo Fisher Scientific Inc. yet.
Thermo Fisher Scientific Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of …
Full company profileThermo Fisher Scientific Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Thermo Fisher Scientific Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.3B | 20.9B | 24.4B | 25.5B | 32.2B | 39.2B | 44.9B | 42.9B | 42.9B | 44.6B | 46.1B |
| Gross Profit | 8.58B | 9.68B | 11.0B | 11.3B | 16.0B | 19.6B | 19.0B | 17.1B | 17.7B | 16.8B | 18.1B |
| Operating Income | 2.86B | 3.27B | 3.87B | 4.26B | 7.90B | 10.3B | 8.53B | 6.86B | 7.66B | 8.11B | 8.48B |
| EBITDA | 4.25B | 5.25B | 6.20B | 6.46B | 10.2B | 13.0B | 11.9B | 10.8B | 11.8B | 11.5B | 11.3B |
| Net Income | 2.02B | 2.23B | 2.94B | 3.70B | 6.38B | 7.73B | 6.95B | 6.00B | 6.34B | 6.74B | 6.79B |
| EPS | 5.09 | 5.59 | 7.24 | 9.17 | 16 | 19 | 18 | 15 | 17 | 18 | 18 |
| Balance Sheet | |||||||||||
| Total Assets | 45.9B | 56.7B | 56.2B | 58.4B | 69.1B | 95.1B | 97.2B | 98.7B | 97.3B | 110B | 114B |
| Total Liabilities | 24.4B | 31.3B | 28.6B | 28.7B | 34.5B | 54.1B | 53.0B | 51.9B | 47.7B | 56.8B | 59.3B |
| Shareholders' Equity | 21.5B | 25.4B | 27.6B | 29.7B | 34.5B | 40.8B | 44.0B | 46.7B | 49.6B | 53.4B | 54.8B |
| Cash & Short-term Investments | 802M | 1.37B | 2.12B | 2.42B | 10.3B | 4.49B | 8.54B | 8.08B | 5.58B | 10.1B | 6.06B |
| Total Debt | 16.6B | 21.0B | 19.0B | 18.5B | 22.5B | 36.3B | 36.1B | 36.7B | 32.8B | 40.9B | 41.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.16B | 4.01B | 4.54B | 4.97B | 8.29B | 9.31B | 9.15B | 8.41B | 8.67B | 7.82B | 7.06B |
| Capital Expenditure | 444M | 508M | 758M | 926M | 1.47B | 2.52B | 2.24B | 1.48B | 1.40B | 1.53B | 1.64B |
| Free Cash Flow | 2.71B | 3.50B | 3.79B | 4.05B | 6.82B | 6.79B | 6.91B | 6.93B | 7.27B | 6.29B | 5.42B |
| Ratios | |||||||||||
| ROE | 9.4% | 8.8% | 10.7% | 12.5% | 18.5% | 18.9% | 15.8% | 12.8% | 12.8% | 12.6% | 12.4% |
| ROA | 4.4% | 3.9% | 5.2% | 6.3% | 9.2% | 8.1% | 7.2% | 6.1% | 6.5% | 6.1% | 5.9% |
| Net Profit Margin | 11.1% | 10.6% | 12.1% | 14.5% | 19.8% | 19.7% | 15.5% | 14.0% | 14.8% | 15.1% | 14.7% |
| Debt to Equity | 0.77x | 0.83x | 0.69x | 0.62x | 0.65x | 0.89x | 0.82x | 0.79x | 0.66x | 0.76x | 0.76x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Thermo Fisher Scientific Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 9.4%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 636M | 1.68 | 9.4% |
| 2024 | USD 583M | 1.52 | 9.2% |
| 2023 | USD 523M | 1.35 | 8.7% |
| 2022 | USD 455M | 1.15 | 6.5% |
| 2021 | USD 395M | 0.99 | 5.1% |
| 2020 | USD 337M | 0.84 | 5.3% |
| 2019 | USD 297M | 0.74 | 8.0% |
| 2018 | USD 266M | 0.66 | 9.1% |
| 2017 | USD 237M | 0.60 | 10.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Thermo Fisher Scientific Inc.
- Insiders 0.13%
- Institutions 93.23%
- Public & others 6.64%
- Free float 370M
Thermo Fisher Scientific Inc. company profile
- Company name
- Thermo Fisher Scientific Inc.
- Ticker
- 0R0H.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 125,000
- Fiscal year end
- December
- Address
- 168 Third Avenue, Waltham, MA, United States, 02451
- Phone
- 781 622 1000
- Website
- thermofisher.com
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Thermo Fisher Scientific Inc. management
10- Mr. Marc N. CasperChairman & CEO · born 1968
- Mr. Gianluca PettitiPresident, COO & President of Products and Technologies · born 1979
- Mr. James R. MeyerSenior VP & CFO · born 1979
- Mr. Joseph R. HolmesVP & Chief Accounting Officer · born 1980
- Mr. Ryan J. SnyderSenior VP & Chief Information Officer
- Dr. Karen E. Nelson Ph.D.Chief Scientific Officer
- Mr. Rafael TejadaVice President of Investor Relations
- Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel
- Ms. Sandy B. PoundVP & Chief Communications Officer
- Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development · born 1960